Intensive versus moderate statin therapy and early graft occlusion after coronary bypass surgery: The Aggressive Cholesterol Therapy to Inhibit Vein Graft.

Slides:

Advertisements

Similar presentations

Previous coronary stents do not increase early and long-term adverse outcomes in patients undergoing off-pump coronary artery bypass grafting: A propensity-matched.

Advertisements

Factors associated with postoperative atrial fibrillation and other adverse events after cardiac surgery Emmanuel Akintoye, MD, MPH, Frank Sellke, MD,

Stephen R. Broderick, MD, MPHS

Off-pump coronary artery bypass grafting does not preserve renal function better than on-pump coronary artery bypass grafting: Results of a case-matched.

Rounding numbers The Journal of Thoracic and Cardiovascular Surgery

The impact of placing multiple grafts to each myocardial territory on long-term survival after coronary artery bypass grafting Danny Chu, MD, Faisal.

One in every 14 patients with early-stage lung cancer is not being treated! Benny Weksler, MD, MBA The Journal of Thoracic and Cardiovascular Surgery

It is not just about surgery versus stereotactic ablative radiotherapy, it is about curing as many patients with lung cancer as possible Alessandro Brunelli,

Randomized controlled trial of brief cognitive behavioral intervention for depression and anxiety symptoms preoperatively in patients undergoing coronary.

Stenting versus coronary artery bypass grafting for unprotected left main coronary artery disease: A meta-analysis of comparative studies Hisato Takagi,

Should all moderate coronary lesions be grafted during primary coronary bypass surgery? An analysis of progression of native vessel disease during a randomized.

Neel R. Sodha, MD, Frank W. Sellke, MD

Right internal thoracic artery or saphenous vein grafting

Does preoperative carotid stenosis screening reduce perioperative stroke in patients undergoing coronary artery bypass grafting? Khalil Masabni, MD,

Cardiac tumors: To treat or not to treat (or both)?

Juan A. Crestanello, MD, Richard C. Daly, MD

Assessment of statin therapy, LDL-C levels, and cardiovascular events among high-risk patients in the United States Sudhir K. Unni, PhD, MBA, Ruben G.W.

Lower graft patency after off-pump than on-pump coronary artery bypass grafting: An updated meta-analysis of randomized trials Hisato Takagi, MD, PhD,

Marc R. Moon, MD The Journal of Thoracic and Cardiovascular Surgery

Strict versus liberal target range for perioperative glucose in patients undergoing coronary artery bypass grafting: A prospective randomized controlled.

Skinning the cat: Another wrinkle for T-tube insertion

Multilevel data analysis: What? Why? How?

How should we treat air leaks?

Harold L. Lazar, MD The Journal of Thoracic and Cardiovascular Surgery

New treatment approaches create new disease processes: A short guide on how to reduce unexpected events to a minimum Martin Czerny, MD, MBA The Journal.

Jennifer S. Lawton, MD, Nader Moazami, MD, Michael K

The unintended consequences in clinical research

Surgical economics: MACRA, MIPS, and bundles—Lessons learned in the first 3 years of a coronary artery bypass grafting alternative payment model Daniel.

The effect of coronary angiography timing and use of cardiopulmonary bypass on acute kidney injury after coronary artery bypass graft surgery Kyungmi.

Left ventricular assist device therapy in a patient with hearing and speech disabilities Sotirios Spiliopoulos, MD, PhD, Vera Hergesell, MD, Otto Dapunt,

It's not “just a shunt” but sometimes it should be…

Fixing the supply problem

Do we need a bibliometrician to know which way the wind is blowing?

Ming Guo, MD, Marc Ruel, MD, MPH

Stephen R. Broderick, MD, MPHS

Open thoracoabdominal aortic repair for chronic type B dissection

Michael Lanuti, MD The Journal of Thoracic and Cardiovascular Surgery

Chronic obstructive pulmonary disease severity influences outcomes after off-pump coronary artery bypass Benjamin Medalion, MD, Michael G. Katz, MD,

Niv Ad, MD, Lawrence M. Wei, MD

Replicating the success of mitral valve repair in the aortic valve

Is endoluminal vacuum therapy “sponge worthy”?

Hisato Takagi, MD, PhD, Takuya Umemoto, MD, PhD

A fate worse than death Jennifer S. Lawton, MD

Case reporter's notebook: The who, what, when, where, how, and why of extraction of a benign intracaval tumor Verdi J. DiSesa, MD, MBA The Journal of.

Marc Licker, MD, John Diaper, RA

Passing the torch The Journal of Thoracic and Cardiovascular Surgery

Prognosis and “granularity”: Building on staging foundations?

Patrick T. Roughneen, MD, Grant T. Fankhauser, MD, Abe DeAnda, MD

Ralph S. Mosca, MD The Journal of Thoracic and Cardiovascular Surgery

Syphilitic aortitis: The bigger picture

In pregnancy, aortic tissue is the issue

The Journal of Thoracic and Cardiovascular Surgery

Discussion The Journal of Thoracic and Cardiovascular Surgery

Apparently, size matters…in congenital heart disease and brain injury

Ventricular assistant in restrictive cardiomyopathy: Making the right connection Robert D.B. Jaquiss, MD The Journal of Thoracic and Cardiovascular Surgery

Spot the mesh: Six-month follow-up

Improved quality and cost-effectiveness of coronary artery bypass grafting in the United States from 1988 to 2005 Howard K. Song, MD, PhD, Brian S. Diggs,

The Robin Hood principle in the treatment of congenital heart disease: Taking technologic developments intended for adults and using it in kids Paul.

After neoadjuvant chemoradiation therapy, predicted pulmonary function may be reduced by 10% Benny Weksler, MD, MBA The Journal of Thoracic and Cardiovascular.

“The more things change…”: The challenges ahead

Large clinical databases for the study of lung cancer: Making up for the failure of randomized trials Chi-Fu Jeffrey Yang, MD, Matthew G. Hartwig, MD,

Appropriate Use Criteria for coronary revascularization in patients with stable ischemic heart disease: What the surgeon needs to know Harold L. Lazar,

Ryan R. Davies, MD The Journal of Thoracic and Cardiovascular Surgery

More than vital: Who bears the burden?

Apples remain apples NO matter what

Lung cancer randomized controlled trials should compare stereotactic body radiation therapy with observation, NOT surgery Raja M. Flores, MD The Journal.

A large international single-center case-series of coronary artery fistulas in children: When high clinical research standards adopted globally create.

Preoperative PFTs: The answer is blowing in the wind

Left atrial to left ventricle bypass for mitral valve stenosis

IS local wound infection rate more important than long-term graft patency in coronary artery bypass grafting? Tomislav Kopjar, MD, PhD, Michael R. Dashwood,

Presentation transcript:

Intensive versus moderate statin therapy and early graft occlusion after coronary bypass surgery: The Aggressive Cholesterol Therapy to Inhibit Vein Graft Events randomized clinical trial Alexander Kulik, MD, MPH, Amy M. Abreu, MPA, BSN, RN, CCRC, Viviana Boronat, MD, MBA, CCRP, Marc Ruel, MD, MPH The Journal of Thoracic and Cardiovascular Surgery Volume 157, Issue 1, Pages 151-161.e1 (January 2019) DOI: 10.1016/j.jtcvs.2018.05.123 Copyright © 2018 The American Association for Thoracic Surgery Terms and Conditions

Figure 1 Study enrollment and follow-up. CK, Creatine kinase; CT, computed tomography; MACE, major adverse cardiovascular event. The Journal of Thoracic and Cardiovascular Surgery 2019 157, 151-161.e1DOI: (10.1016/j.jtcvs.2018.05.123) Copyright © 2018 The American Association for Thoracic Surgery Terms and Conditions

Figure 2 Low-density lipoprotein (LDL) levels during study enrollment. LDL levels significantly declined for patients who received 80 mg atorvastatin compared with those who received 10 mg atorvastatin (analysis of variance P < .0001). *P = .56 at baseline preoperative measurement. †P < .00001 for measurements at 3 months, 6 months, 9 months, and 12 months. The Journal of Thoracic and Cardiovascular Surgery 2019 157, 151-161.e1DOI: (10.1016/j.jtcvs.2018.05.123) Copyright © 2018 The American Association for Thoracic Surgery Terms and Conditions

Figure 3 Vein graft stenosis or occlusion (intention-to-treat analysis). There was no significant difference in the incidence of vein graft occlusion (P = .85) or the combination of vein graft stenosis and occlusion (P = .49) between the 2 groups. The Journal of Thoracic and Cardiovascular Surgery 2019 157, 151-161.e1DOI: (10.1016/j.jtcvs.2018.05.123) Copyright © 2018 The American Association for Thoracic Surgery Terms and Conditions

Atorvastatin 80 mg did not significantly reduce the incidence of vein graft disease. The Journal of Thoracic and Cardiovascular Surgery 2019 157, 151-161.e1DOI: (10.1016/j.jtcvs.2018.05.123) Copyright © 2018 The American Association for Thoracic Surgery Terms and Conditions

Video 1 The lead author explaining the study and the importance of the article. Video available at: https://www.jtcvs.org/article/S0022-5223(18)31865-8/fulltext. The Journal of Thoracic and Cardiovascular Surgery 2019 157, 151-161.e1DOI: (10.1016/j.jtcvs.2018.05.123) Copyright © 2018 The American Association for Thoracic Surgery Terms and Conditions

The Journal of Thoracic and Cardiovascular Surgery 2019 157, 151-161 The Journal of Thoracic and Cardiovascular Surgery 2019 157, 151-161.e1DOI: (10.1016/j.jtcvs.2018.05.123) Copyright © 2018 The American Association for Thoracic Surgery Terms and Conditions